[The effect of galanin on the experimental parkinsonian syndrome in rats induced by the intrastriatal administration of kainic acid].
Experiments in rats showed that intrastriatal administration of kainic acid in a dose of 100 but not 20 ng per side resulted in the development of behavioral disorders reminding those of Parkinsonian syndrome: bradykinesia, increased muscle rigidity, ptosis. Intrastriatal administration of galanin in doses of 10 and 50 ng induced only a decrease of locomotor activity in the "open field". When co-administered with kainic acid (20 ng), galanin displayed a dose-dependent potentiation of behavioral Parkinsonian-like disturbances the severity of which increased depending on the dose used. It is concluded that galanin potentiates the kainic acid-induced development of the generator of pathologically enhanced excitation in the striatum underlying the mechanisms of Parkinsonian syndrome. Thus, the increased galaninergic striatal activity could participate in the mechanisms of the above-mentioned CNS disorders.
Shandra
A A
AA
Mazarati
A M
AM
Servetskiĭ
K L
KL
Kresiun
V I
VI
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002421:Caudate Nucleus; D003342:Corpus Striatum; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D019004:Galanin; D007608:Kainic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008845:Microinjections; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000503:physiopathology; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D009479:Neuropeptides; D010455:Peptides; D019004:Galanin; D007608:Kainic Acid